Log in
Enquire now
‌

US Patent 11365394 Enhanced immune effector cells and use thereof

Patent 11365394 was granted and assigned to Fate Therapeutics on June, 2022 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors
Is a
Patent
Patent
0
Current Assignee
Fate Therapeutics
Fate Therapeutics
0
Date Filed
February 19, 2021
0
Date of Patent
June 21, 2022
0
Patent Applicant
Fate Therapeutics
Fate Therapeutics
0
Patent Application Number
17180585
0
Patent Citations
‌
US Patent 10464989 Polypeptides, cells, and methods involving engineered CD16
‌
US Patent 10927346 Enhanced immune effector cells and use thereof
Patent Citations Received
‌
US Patent 12122846 Chimeric antigen receptor for tumor targeting
0
‌
US Patent 11883432 Chimeric antigen receptor system with adaptable receptor specificity
0
‌
US Patent 11661459 Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
0
Patent Inventor Names
Bahram Valamehr
0
Ryan Bjordahl
0
Jode Goodridge
0
Tom Tong Lee
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
11365394
0
Patent Primary Examiner
‌
Marcia S Noble
0

Find more entities like US Patent 11365394 Enhanced immune effector cells and use thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us